Key result
Pre-procedural von Willebrand Factor abnormalities predicted a significantly higher incidence of major or life-threatening bleeding compared to normal function in patients undergoing surgical aortic valve replacement (53% vs 9%, p<0.001).
Why the study?
Both TAVI and SAVR effectively correct von Willebrand Factor pathologies, but data simultaneously comparing outcomes of both approaches were limited.
Does pre-procedural abnormal von Willebrand Factor function predict major or life-threatening bleeding in patients undergoing TAVI or SAVR for severe aortic stenosis?
Cohort (n=100)
Yes
Does pre-procedural abnormal von Willebrand Factor function predict major or life-threatening bleeding in patients undergoing TAVI or SAVR for severe aortic stenosis?
Absolute Event Rate: 53% vs 9%
p-value: p=<0.001
Pre-procedural abnormal von Willebrand Factor function predicts major or life-threatening bleeding after surgical aortic valve replacement, but not after transcatheter aortic valve implantation.
vWF abnormalities may flag high bleeding risk before SAVR; hypothesis-generating for pre-procedural screening pending prospective validation.
Both transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) have been proven to effectively correct von Willebrand Factor (vWF) pathologies, however there is limited data simultaneously comparing outcomes of both approaches. We prospectively enrolled patients with severe aortic stenosis referred for TAVI (n = 52) or SAVR (n = 48). In each case, vWF antigen (vWF:Ag), vWF activity (vWF:Ac) and activity-to-antigen (vWF:Ac/Ag) ratio were assessed at baseline, 24 h and 72 h after procedure. VWF abnormalities were defined as reduced vWF:Ac/Ag ratio (< 0.8). Bleeding events in both arms were classified according to Valve Academic Research Consortium (VARC-2) definitions. Overall, there was no difference between patients referred for TAVI and SAVR in vWF:Ac (1.62 ± 0.52 vs 1.71 ± 0.64; p = 0.593), vWF:Ag (1.99 ± 0.81 vs 2.04 ± 0.81; p = 0.942) or vWF:Ac/Ag ratio (0.84 ± 0.16 vs 0.85 ± 0.12; p = 0.950). Pathological vWF:Ac/Ag ratio was found in 20 (38%) TAVI and 15 (31%) SAVR patients (p = 0.407). Normalization of vWF:Ac/Ag ratio at day 3 after procedure was achieved in 19 (95%) TAVI and 13 (87%) SAVR patients (p = 0.439). Similar prevalence of major or life-threatening bleedings (MLTB) after TAVI and SAVR in entire groups was observed (19% vs. 23%, p = 0.652). VWF abnormalities were associated with higher incidence of MLTB in SAVR (53% vs 9%, p < 0.001), but not TAVI (15% vs. 22%, p = 0.132). Accordingly, in receiver-operating characteristic curve analysis vWF:Ac/Ag ratio < 0.8 showed significant sensitivity and specificity for predicting MLTB in SAVR group (AUC 0.735, 95% CI 0.538-0.931, p = 0.019). We proved that abnormal function of vWF is corrected successfully after both TAVI and SAVR, but vWF abnormalities are predictive of MLTB only in surgical patients.
No takes yet. Share an insight, caveat, or question.
Grodecki et al. (2019) conducted a cohort in Severe symptomatic aortic stenosis (n=100). Pre-procedural von Willebrand Factor abnormalities vs. Normal von Willebrand Factor function was evaluated on Major or life-threatening bleeding (MLTB) in SAVR patients (p=<0.001). Pre-procedural von Willebrand Factor abnormalities predicted a significantly higher incidence of major or life-threatening bleeding compared to normal function in patients undergoing surgical aortic valve replacement (53% vs 9%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: